COVID-19

News

Generic pill could be alternative to oral antivirals in COVI...

A generic pill has been shown to reduce hospitalisation rates in high-risk patients with early COVID-19, potentially offering a low-cost alternative to oral antivirals from Merck & Co a

News

CDC director backs COVID-19 jab for 5 to 11s, plus a fourth ...

The US looks set to see a big expansion of the country's COVID-19 vaccination drive, with shots looking likely for children aged five to 11 as well as a fourth dose for adults who are immun

News

GSK side-lines COVID drug otilimab to focus on Xevudy

GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on Xevudy for mild-to-moderate diseas

News

Merck takes further steps to expand access to oral COVID pil...

Merck & Co has signed a licensing deal with the UN-backed Medicines Patent Pool (MPP) that could pave the way for generic companies to manufacture its much-anticipated oral antiviral fo

Sales & Marketing

Sustained healthcare systems need sustainable pharma busines...

COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing.

News

EU starts review of Merck's oral COVID drug molnupiravir

The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics' much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults.

Generic pill could be alternative to oral antivirals in COVI...

CDC director backs COVID-19 jab for 5 to 11s, plus a fourth ...

GSK side-lines COVID drug otilimab to focus on Xevudy

Merck takes further steps to expand access to oral COVID pil...

Sustained healthcare systems need sustainable pharma busines...

EU starts review of Merck's oral COVID drug molnupiravir

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

COVID-19

Editor's Picks